Thomas Sidwell

6 Medical Device Makers Poised for Growth

Polaris: ISRG is included in the list not because of necessarily a lack of sales growth or profitability, but rather because I believe that they should do EVEN BETTER as the cruch lessens. You cannot deny that ISRG is $80 off of its high. I have no financial interest in any of these companies, and infer rather you do from your incredibly hostile post.

phil_vardena: I don't know how to address your comments as outright like polaris. I do not know how many of the core abstracts truely relate to the Niobe system and how many of them are good. Undeniably Stereotaxis trails Hansen overall in production and approval currently, whether or not you believe they have a better product. Nevertheless, the market certainly like Hansen much more than Stereotaxis, and it is poised for profitability considerably sooner than Stereotaxis. As I said in the Article, I think that Stereotaxis remains an attractive buyout for Hansen should competition increase, and if their product is better, of which I, nor the medical community is 100% convinced, they will combine with Hansen. Something you are also overlooking is the overall connections and leadership of Dr. Moll in this field. Again, I have no financial interest in Hansen.